When the DNA's nucleotide sequence is changed and a new sequence is transmitted to the progeny, this is known as a gene mutation. A single or a few nucleotides may be changed for others, or a single or a few pairs of nucleotides may be added or removed. The letters A, C, G, and T, respectively, stand in for the four nucleotide bases of DNA, adenine, cytosine, guanine, and thymine. Each section of three nucleotides-referred to as a triplet or codon-in a gene's sequence, which contains the instructions for building a protein molecule, codes for a specific amino acid in the protein. In which the viral genomes either contain DNA or RNA. Recurrent gene mutations are characterized by Acute Myeloid Leukemia (AML), a genetically diverse clonal cancer. The biggest challenges to the therapeutic effectiveness of AML patients include genomic heterogeneity, patient individuality, and recurrent gene alterations. An enormous variety of genetic mutations have been discovered thanks to the use of Next-Generation Sequencing (NGS) technology, which are both cost- and time-efficient. Various studies have been conducted on the recurring gene mutations and the significant roles they play in the pathogenesis of AML. The failure of differentiation and unchecked proliferation of hematopoietic progenitor cells lead to a variety of clonal diseases of AML. Gene mutations and several cytogenetic abnormalities can assemble simultaneously. It is now more feasible for clinical research to investigate cytogenetic analysis in many different disorders, including AML, thanks to recent improvements in NGS. After undergoing the recommended first-line chemotherapy regimen, the majority of AML patients can now achieve Complete Remission (CR) because to advancements in chemotherapy. Many patients can experience extended remission-free survival periods by combining chemotherapy, hematopoietic stem cell transplantation, immunotherapy, and molecular targeted therapy with conventional types of treatment. The preferred first-line treatment for AML is still acknowledged as the standard therapy of daunorubicin and cytarabine induction chemotherapy. Prognostically different cytogenetic subgroups were tightly related with certain gene mutations. Additionally, multivariate analysis showed that patient age affects how some mutations are felt. We looked at patient subsets sorted by age and cytogenetics to make it easier to evaluate these results and see how co-occurring gene mutations affect survival together. The time from diagnosis to the end point, such as death or the last follow-up, is known as Overall Survival (OS). Journal URLs https://www.walshmedicalmedia.com/clinical-medical-biochemistry.html Submission url: https://www.walshmedicalmedia.com/clinical-medical-biochemistry/submit-manuscript.html Instructions for author: https://www.walshmedicalmedia.com/clinical-medical-biochemistry/instructionsforauthors.html https://www.walshmedicalmedia.com/clinical-medical-biochemistry/archive.html https://www.walshmedicalmedia.com/clinical-medical-biochemistry/ethical-malpractices.html